A CRISPR‑based gene editing therapy from CRISPR Therapeutics reported dramatic reductions in LDL cholesterol and triglycerides in an early human study, according to data presented at a major cardiology meeting and published in the New England Journal of Medicine. The single‑course editing approach produced sustained lipid lowering in a small cohort, prompting both enthusiasm and caution about liver toxicity and the ethics of permanent edits for common diseases. Investigators highlighted pronounced biomarker changes but noted limited patient numbers and the need for larger safety datasets. The trial frames gene editing as a potential one‑time intervention for cardiovascular risk, while underscoring regulatory and patient‑acceptance hurdles. Next steps include expanded safety monitoring, dose optimization and debate over clinical indications where permanent editing is acceptable relative to reversible pharmacotherapies.